Cigarette Smoking — Body Handbook

Breathing · §23

Cigarette Smoking

Smoking is the largest preventable cause of early death in modern medicine — about a decade of life lost on average, most of it the retirement decade you were saving for. The counterintuitive part is how fast the body backs out of it: heart rate normalises in twenty minutes, carbon monoxide clears in twelve hours, coronary risk halves inside a year. The catch — and where most quit attempts come undone — is that nicotine makes this one of the harder behaviour changes you'll attempt, and unaided willpower succeeds well under 10% of the time.

Avoid · Daily Evidence Strong Chapter Breathing

The dominant number is longevity: smoking is the single largest preventable hazard in modern medicine, and quitting before 40 reclaims roughly 90% of the years it would otherwise cost. Lung-cancer and cardiovascular risk fall on a measured schedule that begins within a day. Skin, taste, energy, sleep and mood all improve too, mostly within weeks to months. The honest catch: nicotine is genuinely addictive, and most people need several attempts plus medication to make it stick — earlier is much easier than later.

What smoke does to the body splits into two parallel injury streams. The first is oxidative: every puff drops a load of reactive oxidants and carbon monoxide into your lungs and bloodstream. Carbon monoxide binds red blood cells about 240 times harder than oxygen does, so heavy smokers walk around with 5–10% of their oxygen-carrying capacity offline. The oxidants meanwhile chew up the inner lining of blood vessels — endothelium — and that's the trigger for the chronic inflammation that builds plaque Gallucci 2020. Six interlocking mechanisms feed coronary disease this way: blood-vessel damage, sticky platelets, inflammation, worse cholesterol, more cardiac oxygen demand from a revved sympathetic nervous system, and less supply because of the carbon monoxide Surgeon General 2014.

The second stream is cancer chemistry. Smoke carries dozens of substances that latch onto DNA and force it to copy with errors. Tumours show up where the smoke touches directly — lung, voice box, mouth, throat, oesophagus — and where the body excretes the smoke's by-products: bladder, kidney, pancreas. Lung tumours from smokers carry a specific mutation fingerprint that rises in lockstep with how long the person smoked Surgeon General 2014.

In the airway itself, smoke triggers chronic inflammation, paralyses the small hairs that sweep mucus out, and slowly destroys the air sacs themselves — the path to chronic obstructive pulmonary disease (COPD). Skin shares roots with the vascular story: chronic dermal vessel constriction plus enzymes that break collagen down faster than it's rebuilt is what produces the perioral lines and the greyish cast clinicians used to call "smoker's face".

How sure we are

The numbers come from cohorts measured in millions of people across decades — Doll's British doctors, Jha's US adults, Pirie's UK women. They converge tightly: smokers' all-cause death rate is about three times never-smokers', and life expectancy is shortened by more than a decade Jha 2013 Doll 2004 Pirie 2013.

Lung cancer is the loudest cause-specific signal — about 8× the never-smoker risk across 287 studies, climbing past 18× for the heaviest small-cell tumours Lee 2012. It's also why two decades of smoking earns you a yearly low-dose CT — lung-cancer screening — that catches tumours early, while they're still treatable. But the formally-recognised list runs much longer: cancer of the lung, voice box, mouth, throat, oesophagus, stomach, liver, pancreas, kidney, bladder, cervix, colon and rectum, plus a form of leukaemia Surgeon General 2014. Cardiovascular disease is the larger total killer — smoking roughly doubles your 10-year risk of a fatal heart attack, with damage that scales near-linearly from very low exposure Gallucci 2020.

The reproductive numbers are real and dose-dependent: smokers' sperm carries lower count, lower motility, and more shape defects Sharma 2016; erectile dysfunction is about 50% more likely in current smokers than never-smokers Cao 2013. In pregnancy, smoking raises the odds of stillbirth by 47% — 52% in mothers smoking ten or more a day — and the odds of low birthweight by 89% Marufu 2015 Quan 2021. A more recent pooled analysis of about a million US adults found the total smoking-attributable death count had been underestimated by roughly 17% in earlier work — kidney failure, infections, bowel ischaemia and several other causes turned out to be smoking-driven too Carter 2015.

What continues if you don't stop

Picture the 35-year-old who keeps going. Most of what's coming isn't dramatic. The morning cough sticks around and gets a bit louder. Stairs start counting in a way they didn't at 28. Friends who quit slowly look younger than you in photos — the perioral lines around the lips, the greyish cast in the cheeks, the lines clinicians used to spot at a glance. Sex life: a partner trying to conceive notices things taking longer than friends'; the erectile dysfunction risk creeps up about 50% over never-smokers' Cao 2013. In your fifties, exercise tolerance has clearly diverged from peers — the flight of stairs at the office is now what you used to feel at the gym.

Then somewhere in the sixties, the curve steepens. Doll's half-century follow-up of British doctors and Jha's analysis of US adults both landed on the same number: continuous smokers died about a decade younger than lifelong non-smokers Doll 2004 Jha 2013. The Million Women Study found the same hazard pattern in women — and importantly, even women smoking fewer than ten a day doubled their twelve-year death rate Pirie 2013. It is the single most preventable thing the average reader could remove from their own life expectancy, and most of what gets removed is the retirement decade.

How to quit so it sticks

Quitting is the protocol. The single biggest signal from the cessation literature: medication plus structured support roughly triples your odds of long-term success versus white-knuckle willpower Surgeon General 2020. The current Cochrane ranking puts varenicline (a prescription pill that occupies nicotine receptors) at the top, comparable to combining a long-acting nicotine patch with short-acting nicotine gum or lozenges — called combination nicotine replacement therapy, or NRT. Single-form NRT (a patch alone) and bupropion (an antidepressant repurposed for cessation) sit roughly tied a step behind. Nicotine e-cigarettes now rate as effective cessation aids on high-certainty evidence, with the caveat that decade-plus safety data isn't in yet — but switching to vaping is a substantial harm reduction over continuing to smoke Lindson 2023.

In the US, the Affordable Care Act preventive-services mandate requires most insurance plans to cover cessation medication with no copay. The UK NHS Stop Smoking Services provide medication and behavioural support free. The cost of quitting is, in practice, the absence of the $3,000–$5,500 you were spending annually on cigarettes.

Cessation medications — when not to use

Smoking itself has no clinical contraindication; it's harmful in every population studied. But several conditions raise the urgency from years-of-life timescale to immediate-clinical: a recent heart attack, current pregnancy, established COPD, and the run-up to most surgeries. In those contexts cessation is the highest-leverage single intervention available, often outperforming the medications added on top Surgeon General 2020.

What most people get wrong

"Light smoking is safe." The Million Women Study followed 1.3 million women — those smoking fewer than ten a day still doubled their twelve-year death rate versus never-smokers Pirie 2013. The cardiovascular dose-response runs near-linear from very low exposure; there's no safety threshold below which the risk evaporates.

"I'm too old, the damage is done." Doll's data is the cleanest refutation. Stopping at 60 still buys back about three years of life expectancy; stopping at 50 buys six; at 40, nine; at 30, ten Doll 2004. Coronary risk halves within a year of cessation regardless of age.

"Smoking helps me focus / calms me down." Nicotine is acutely pro-cognitive in the moment of a cigarette, which is real. But the chronic picture works against focus: the inter-cigarette withdrawal nibbles at attention through the rest of the day, and the carbon-monoxide load reduces oxygen to the brain. On mood, smokers actually run higher rates of anxiety and depression than non-smokers; the "calm" of a cigarette is mostly the relief of the craving the previous cigarette set up. Mood lifts measurably about six months after the last one, once withdrawal is fully behind you Surgeon General 2020.

"I'd just gain weight." Average post-cessation weight gain is 4–5 kg and plateaus around year one — small next to the cardiovascular and cancer payoff of stopping. Even at 5 kg, the gain doesn't begin to offset what continuing smoking does to all-cause mortality.

"Antioxidant supplements will mop up the damage." They won't — and one in particular backfires. High-dose beta-carotene is the supplement smokers should specifically skip: in trials it raised lung-cancer rates rather than lowering them, the opposite of why people took it. (More under vitamin A.)

"Hand-rolled, natural, menthol, or low-tar is safer." None has held up in cohort data. Menthol cigarettes may actually be worse — the cooling sensation lets smokers inhale more deeply.

"It's the nicotine that kills you." Nicotine is the addictive agent, not the cancer driver. It's the combustion products — tar, oxidants, carbon monoxide, the carcinogen panel — that produce the disease burden. This is the conceptual basis for nicotine replacement therapy and for harm reduction with e-cigarettes: keep the nicotine that keeps you off cigarettes, lose the combustion that kills you.

Where quits go wrong

The most common pattern is unaided willpower-only attempts. These succeed long-term at roughly 3–7% per try, and a single failed attempt is often taken as evidence that quitting won't work for you Surgeon General 2020. It isn't. The median person who succeeds has tried six to eleven times before one stuck — each failed attempt is part of the learning curve, not the verdict on whether you can do it.

Other common ways a quit falls apart:

Stopping medication too early. The 8–12 week course is what the trials are built on; cutting it to two weeks roughly halves the benefit.
Under-dosing NRT. Most people wear the patch and skip the short-acting gum or lozenge — combination NRT is what matches varenicline in effect; patch alone is a step behind.
Trying to quit during an acute stressor — a work crisis, a bereavement, a move — without scheduled support lined up.
Alcohol co-use. The highest-risk relapse context by a wide margin. If you can dial it down for the first few months, do.

What changes when you stop

The body backs out of smoking faster than almost any other accumulated harm in medicine. The recovery is graded, scheduled, and well-documented Surgeon General 2014 Surgeon General 2020.

First day. Heart rate and blood pressure drop within twenty minutes. Carbon monoxide clears within twelve hours and oxygen-carrying capacity is restored. The hand-shaking, irritability and craving are real but front-loaded — most peak inside 72 hours.

First month. Taste and smell sharpen. Food starts hitting differently. The morning cough quietens. The hands and clothes stop carrying the smell that other people had been clocking for years before you did. Sleep settles back into a normal architecture after a rough first week or two.

First year. Excess coronary heart disease risk halves. Lung capacity climbs back through several percentage points Anthonisen 1994. Skin tone improves visibly as the small dermal vessels stop constricting all day — colleagues start asking if you've been on holiday. Erectile function tracks back toward never-smoker baseline within months Cao 2013.

Five years. Stroke risk approaches a never-smoker's. Cancer risk at the mouth, throat, oesophagus and bladder is roughly halved.

Ten years. Lung cancer mortality risk halves versus continuing smokers (it never quite returns to a never-smoker's baseline, but the gap closes substantially).

Fifteen years. Coronary heart disease risk approaches a never-smoker's. By now the cardiovascular profile is largely indistinguishable from someone who never picked up the habit.

The lifespan arithmetic underneath all this, from the two big cohorts: quit by 30, reclaim about ten years. Quit by 40, reclaim about nine. By 50, six. By 60, three Jha 2013 Doll 2004. The retirement decade smoking was going to subtract — most of it stays in the account.

Adjacent topics worth looking into separately: nicotine vaping as a harm-reduction route (different substance, different risk profile), secondhand and household smoke exposure for partners and children, smokeless tobacco (chewing tobacco, snus), cannabis combustion, and structured cessation programmes built for specific populations like pregnancy and severe mental illness.

Related in the handbook

Worsens / aggravates

— Smoking weakens the aortic wall; ex-smokers over 65 are the group the one-time aneurysm ultrasound is built for.
— Smoking is the main driver of COPD — and quitting is the single biggest move once you're diagnosed.
— Smoking damages the small vessels that drive an erection — a common, often reversible cause that improves after you quit.
— Hidradenitis suppurativa is among the skin diseases smoking clearly makes worse.
— Smoking hits the smallest arteries first; losing your morning erections is an early, visible warning the damage has started.
— Smoking narrows the small arteries in your fingers and toes, making cold-triggered attacks like Raynaud's worse.
— Smoking is one of the biggest drivers of gum disease — and it masks the bleeding warning sign, so damage runs silent until it's advanced.
— Smokers should skip high-dose beta-carotene supplements; the combination raised lung-cancer rates in trials.
— Smoking quietly thins your bones — a real, modifiable driver of the fractures that come later.

Helps

— Tried everything to quit? TMS, the depression device, is also cleared for smoking cessation and beats the odds in hard cases.

Diagnosis

— Twenty years of smoking earns you a yearly scan that cuts your odds of dying from lung cancer by a fifth.

Alternatives

— For a smoker who can't quit other ways, switching fully to a vape captures most of the years cigarettes were taking.

— Smoking status is a direct input to the PREVENT heart-risk score. Quitting is one of the fastest ways to drop the number it gives you.
— Smoking and very hot drinks compound — the same hot cup is far riskier if you smoke.

Substance and claimed effects

Cigarette smoking — the daily, repeated inhalation of combusted tobacco smoke — is the most studied modifiable health behaviour in the medical literature. The substance combines pharmacologically active nicotine (the dependence-producing agent) with thousands of combustion products including tar, carbon monoxide, polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, hydrogen cyanide, formaldehyde and reactive oxidant species. The 2014 US Surgeon General's report USSG 2014 formally attributes causation to disease across nearly every organ system in the body. This entry covers the substance and its meaningful consequences across the dimensions named in the brief: cardiovascular disease, lung function (including COPD), cancer at multiple sites, skin and visible appearance, male and female fertility, all-cause lifespan, and the time-graded reversal of these risks after cessation. Smoking is an avoid entry — the action the reader takes is to not start, or to stop.

Evidence by addressing question

mechanism

Two parallel injury cascades drive almost everything smoking does to the body. First, the combustion stream delivers a high oxidant load directly into the lungs and, via blood, to systemic endothelium. Reactive oxygen species in smoke quench nitric oxide and damage the endothelial monolayer, reducing flow-mediated dilation and triggering the chronic vascular inflammation that produces atherosclerosis Gallucci 2020. The Surgeon General lists six interlocking cardiovascular mechanisms: endothelial damage, prothrombotic state (platelet activation, increased fibrinogen), systemic inflammation, dyslipidaemia (raised LDL, lowered HDL), increased myocardial oxygen demand from sympathetic activation, and decreased oxygen supply from carbon monoxide displacement of haemoglobin USSG 2014. Carbon monoxide binds haemoglobin with ~240× the affinity of oxygen; carboxyhaemoglobin levels in heavy smokers run 5–10% versus <1% in non-smokers, directly reducing oxygen delivery.

Second, the carcinogen panel — benzo[a]pyrene, N-nitrosamines (NNK, NNN), aromatic amines — forms covalent adducts with DNA. When repair fails, signature mutations accumulate in epithelia directly exposed (bronchial, oral, laryngeal, oesophageal) and in epithelia downstream of metabolised carcinogen excretion (bladder, kidney, pancreas). The mutational signature of tobacco smoke (Alexandrov SBS4) is detectable in lung tumours and rises monotonically with pack-years USSG 2014.

In the airway, smoke triggers chronic neutrophilic inflammation, protease–antiprotease imbalance (elastase versus α1-antitrypsin), goblet-cell hyperplasia, ciliary paralysis, and the small-airway remodelling and alveolar destruction that constitute COPD. Skin effects share roots with vascular pathology: chronic dermal microvascular constriction plus matrix metalloproteinase upregulation (MMP-1 in particular) accelerates collagen and elastin breakdown.

evidence

The evidence base on smoking is among the largest in human medicine — over a million deaths analysed across multiple large prospective cohorts with multi-decade follow-up.

All-cause mortality. The Jha et al. 2013 NEJM analysis of 202,248 US adults (National Health Interview Survey linked to mortality) found current smokers' all-cause death rate was approximately three times that of never-smokers, with life expectancy shortened by more than 10 years Jha 2013. The 50-year follow-up of the British Doctors' Study (34,439 men) found the same 10-year life-expectancy gap, with stopping at 60/50/40/30 returning 3/6/9/10 years of life respectively Doll 2004. The Million Women Study (1.3M UK women) reported a mortality rate ratio of 2.76 (95% CI 2.71–2.81); two-thirds of female smokers aged over 50 will die from smoking-related disease, but quitting before 40 averts about 90% of the excess risk Pirie 2013.

Cause-specific mortality. In the Jha cohort, hazard ratios for cause-specific death in current smokers were: lung cancer HR 17.8 (women) / 14.6 (men); other respiratory diseases (COPD-dominated) HR 8.5 / 9.0; ischaemic heart disease HR 3.5 / 3.2 Jha 2013. The Carter et al. 2015 NEJM pooled analysis of ~1 million participants identified additional causally-linked deaths beyond the previously-recognised set (renal failure, infections, ischemic bowel) that bring smoking-attributable mortality estimates up by ~17% Carter 2015.

Lung cancer. A 2012 meta-analysis of 287 studies put the relative risk of lung cancer at 8.43 for current smokers versus never-smokers, with intensity-stratified ORs ranging up to 18.3 for small-cell carcinoma in the heaviest-smoking categories (≥30 cig/day) Lee 2012.

Cardiovascular. Smoking approximately doubles 10-year risk of fatal coronary events; the effect is dose-dependent but with a striking near-linear extension into the low-exposure range — even <5 cig/day produces ~40–50% of the cardiovascular risk of pack-a-day smoking Gallucci 2020.

Pregnancy. Maternal smoking increases stillbirth odds by 47% (OR 1.47, 95% CI 1.37–1.57), with a clear dose-response: 1–9 cig/day raises odds 9%, ≥10/day raises odds 52% Marufu 2015. Low birthweight OR is 1.89 (55-study meta-analysis) Quan 2021.

Fertility. A 2016 meta-analysis of 5,865 men found significantly reduced sperm count, motility and normal morphology in smokers, with effect size scaling with smoking intensity and exceeding the WHO lower reference limit for clinical infertility in heavy smokers Sharma 2016. Erectile dysfunction risk: current-smoker OR 1.51, former-smoker OR 1.29 versus never-smokers in a meta-analysis of 28,586 men Cao 2013.

Lung function recovery. The Lung Health Study (Anthonisen et al., 5,887 middle-aged smokers with mild airflow obstruction, 14-year follow-up) is the canonical RCT of cessation: sustained quitters had FEV₁ decline 28 mL/year, intermittent quitters 48 mL/year, continuing smokers 62 mL/year. The development of clinically significant airway obstruction was largely prevented in those who quit Anthonisen 1994.

Visible aging. Model's 1985 BMJ characterisation of "smoker's face" — accentuated nasolabial and perioral wrinkling, gaunt cheeks, greyish complexion — has been replicated by multiple controlled image-analysis studies; smokers in their 40s commonly show wrinkle counts equivalent to non-smokers in their 60s Model 1985.

protocol

The protocol is cessation. The 2020 Surgeon General's report on smoking cessation is the consensus reference: pharmacotherapy plus behavioural support roughly doubles or triples successful quit rates over willpower-alone USSG 2020. The Cochrane component network meta-analysis (Lindson et al. 2023) ranks first-line pharmacotherapy:

Varenicline: RR for sustained abstinence 2.32 (95% CI 2.15–2.51) versus placebo (41 trials, 17,395 participants). Most effective single agent.
Combination NRT (long-acting patch + short-acting gum/lozenge/inhaler/spray): RR comparable to varenicline.
Single-form NRT: RR ~1.55–1.60 versus placebo; varenicline beats single-form NRT (RR 1.25, 95% CI 1.14–1.37).
Bupropion: RR ~1.60 versus placebo; varenicline beats bupropion (RR 1.36, 95% CI 1.25–1.49).
Cytisine: emerging evidence comparable to varenicline; widely used in Eastern Europe.
Nicotine e-cigarettes: now rated by Cochrane as having high-certainty evidence of greater quit-rate efficacy than NRT (RR 1.59, 95% CI 1.29–1.93), with the caveat that long-term safety beyond ~2 years is unestablished Lindson 2023.

Behavioural support — text-message programmes, telephone quitlines, structured counselling, group programmes — adds an independent ~10–15% to quit rates and combines additively with pharmacotherapy.

Cessation timeline. The Surgeon General's reports document a graded recovery USSG 2014 USSG 2020:

20 minutes: heart rate and blood pressure drop toward baseline.
12 hours: blood carbon monoxide normalises; haemoglobin oxygen-carrying capacity restored.
2 weeks – 3 months: circulation improves; FEV₁ begins improving.
1–9 months: cilia regrow, cough and dyspnoea decrease.
1 year: excess coronary heart disease risk halved.
5 years: stroke risk approaches never-smoker baseline; oral, throat, oesophageal, bladder cancer risk halved.
10 years: lung cancer mortality risk roughly halved versus continuing smokers (never returns fully to never-smoker baseline).
15 years: coronary heart disease risk approaches never-smoker baseline.

The life-expectancy gain from quitting (Jha 2013, Doll 2004 corroborate): quitting by age 30 returns ~10 years; by 40 returns ~9 years; by 50 returns ~6 years; by 60 returns ~3 years. Even quitting late offers meaningful gain; the message is that earlier is dramatically better but it is never too late Jha 2013 Doll 2004.

contraindications

Standard pharmacotherapy contraindications are well-mapped USSG 2020:

Bupropion: contraindicated in seizure disorders, eating-disorder history, current MAOI use. Caution in bipolar disorder.
Varenicline: dose-reduce in severe renal impairment; the historical FDA black-box warning for neuropsychiatric events was removed in 2016 after EAGLES (8,144-participant trial) found no excess versus placebo, NRT, or bupropion.
NRT in pregnancy: lower nicotine doses than smoking deliver; behavioural support is first-line in pregnancy but NRT is preferred over continued smoking when needed.
E-cigarettes in pregnancy and youth: not recommended; data inadequate.

Smoking itself has no clinical contraindication — the behaviour is harmful in every population studied. But certain comorbidities (recent MI, pregnancy, COPD, post-surgical recovery) raise the urgency of cessation from years-of-life to immediate-clinical-outcome scale.

misconceptions

"Light smoking is safe." Pirie 2013 found that women smoking <10 cig/day still had double the 12-year mortality of never-smokers Pirie 2013. The dose-response is steep at the low end for cardiovascular endpoints — there is no safe threshold.
"Quitting later is pointless / damage is done." Doll 2004 specifically refutes this: quitting at 60 still returns ~3 years of life Doll 2004. Cardiovascular risk halves within a year of cessation regardless of age.
"I'd gain too much weight if I quit." Average post-cessation weight gain is 4–5 kg, plateaus around year 1, and is dwarfed by the cardiovascular and oncologic benefits of cessation in every cohort analysis.
"Hand-rolled / 'natural' / menthol / low-tar cigarettes are safer." None of these is safer in any large cohort; some (menthol) facilitate deeper inhalation and may be worse.
"It's the nicotine that kills you." Nicotine is the addictive agent but is not the principal driver of cancer or cardiovascular mortality — the combustion products are. This is the conceptual basis for harm reduction with vaping/NRT.
"Vaping is just as bad." Acute toxicity profile is substantially lower than combusted tobacco; long-term outcomes remain under investigation, but Cochrane now rates nicotine e-cigarettes as effective cessation aids with high-certainty evidence Lindson 2023.

failure-modes

The most common failure mode is single-modality willpower-only attempts. Unaided quit attempts succeed long-term at roughly 3–7% per attempt; pharmacotherapy plus behavioural support roughly triples that USSG 2020. The median successful quitter makes ~6–11 attempts before achieving sustained abstinence — relapse is the norm, not a personal failure, and reattempt within weeks of relapse is the protocol. Other failure modes: stopping pharmacotherapy too early (the 8–12 week course matters), under-dosing NRT (most users use too little patch + no short-acting), trying to quit during an acute stressor (work crisis, bereavement) without scheduled support, and bidirectional triggers (alcohol co-use is the highest-risk relapse context).

stakes

The reader-relevant stakes are: a typical 35-year-old smoker who continues is choosing, in expectation, to lose about a decade of life — most of it the final retirement decade — and to spend years before that with diminished function (breathlessness on stairs, reduced exercise capacity, impotence risk, worsening skin) Doll 2004 Jha 2013. The Pirie cohort shows the effect is symmetric in women Pirie 2013. For partners, fertility delays of months to years are typical; for the next generation, pregnancy smoking elevates stillbirth and low-birthweight risk substantially Marufu 2015 Quan 2021.

payoff

Cessation produces the most rapidly-reversing risk profile in modern preventive medicine. The first day delivers a measurable cardiovascular signal (heart rate, blood pressure, CO clearance); the first year halves the excess coronary risk; the first decade brings lung cancer risk down by half; by 15 years the cardiovascular profile is largely indistinguishable from never-smokers. The Jha and Doll cohorts independently quantify the life-expectancy reclamation: quit by 30, gain ~10 years; quit by 40, gain ~9 years; quit by 50, gain ~6 years Jha 2013 Doll 2004. Subjective gains the reader can expect: taste and smell return within weeks, exertion tolerance improves over months, skin tone improves perceptibly over 6–12 months (improved microcirculation), and the chronic morning cough resolves within months.

practicalities

A pack-a-day habit at US/UK prices runs roughly $3,000–$5,500/year. Pharmacotherapy is comparatively cheap: varenicline generic ~$200–400/12-week course, NRT patches plus gum ~$150–300/course, bupropion generic ~$50–100/course. Most US insurance plans now cover cessation pharmacotherapy with no copay (Affordable Care Act preventive-services mandate); UK NHS provides free cessation pharmacotherapy and behavioural support through stop-smoking services. Quitline access (1-800-QUIT-NOW in the US, NHS Smokefree in the UK) is free.

The credibility range

Optimist case (for cessation). Smoking is the most preventable cause of death in modern medicine; the evidence base is the largest and most internally consistent of any modifiable risk factor. Multiple million-participant cohorts converge on the same numbers across cultures and decades. The pharmacotherapy toolkit is mature and inexpensive; insurance coverage is broad. Even partial success — switching from combusted tobacco to nicotine e-cigarettes — produces a substantial expected health gain, and Cochrane now endorses this on high-certainty evidence. A reader who quits by 40 has near-complete reclamation of life-expectancy.

Skeptic case. The cessation literature concentrates on the easy outcomes — sustained abstinence at 6–12 months — and the success rates remain modest (15–35% with optimal pharmacotherapy at 6 months, falling further at 5 years). E-cigarette long-term safety beyond ~2 years is not established; the vaping-induced lung injury (EVALI) episode of 2019 was traced to additive contamination rather than to nicotine vaping per se, but the lack of decades-long cohort data is a genuine gap. The dose-response near zero is real but uncertain; whether ultra-light social smoking carries the same proportional risk as steady low-volume daily smoking is not fully settled.

Author's call. This is one of the clearest, highest-evidence calls in the catalogue: avoid starting, and if smoking, quit. The marginal cost-benefit of quitting outweighs nearly every other preventive intervention available. Controversy score is essentially zero (no credible scientific position defends smoking continuation); evidence score is at the ceiling. The action is unambiguous; the difficulty is behavioural, not epistemic.

Stakeholder and incentive map

Tobacco industry. Commercial incentive to retain smokers and recruit new ones; well-documented historical suppression of internal evidence (the Master Settlement Agreement documents). Now diversified into heat-not-burn and nicotine-pouch products.
E-cigarette industry. Mixed — some firms are independent harm-reduction advocates, others are tobacco subsidiaries (Juul–Altria, Vuse–RJ Reynolds, Blu–Imperial). Incentive structure is complicated.
Pharma. Modest commercial interest in varenicline (Pfizer, generic since 2021), NRT (J&J Nicorette franchise, GSK Nicoderm). Bupropion is generic and cheap.
Public health bodies. CDC, NHS, WHO, USPSTF, FDA all aligned on cessation. Disagreement is real between US public-health bodies (cautious on e-cigarettes for cessation) and UK bodies (Public Health England, NICE — more permissive on e-cigarettes as harm reduction). This affects the practical messaging more than the underlying evidence.
Patients. Strong cultural identity component in some smoking communities; cessation is sometimes resisted as identity loss, not just chemical withdrawal.

Population variability

Sex. Women appear at slightly higher proportional risk for some smoking-related outcomes (lung cancer, especially adenocarcinoma) at equivalent exposure, possibly due to differences in carcinogen metabolism and lung architecture USSG 2014. Otherwise the hazard profile is largely symmetric.
Age at start. Earlier initiation (teenage) produces greater lifetime hazard; nicotine dependence consolidates faster in adolescent brains. Three-quarters of US adult smokers started before age 18.
Age at cessation. Sharply graded benefit by age at quit (Doll 2004, Jha 2013): quitting before 40 recovers ~90% of excess mortality risk; quitting at 60 still recovers ~30%.
Genetic susceptibility. α1-antitrypsin deficiency dramatically accelerates COPD onset in smokers; some CYP1A1/GSTM1 variants modulate lung cancer susceptibility. Clinically these are minor compared to the smoking signal itself.
Pregnancy. Special-population because effects are on both mother and fetus, and the timescale matters (any smoking during pregnancy carries elevated risk; quitting at any gestational age helps).
Mental illness. Smoking prevalence runs 2–3× higher in schizophrenia, bipolar disorder, and severe depression. Cessation is achievable in these populations but requires more intensive support; varenicline and bupropion both tested as safe (EAGLES trial).
Pre-existing cardiovascular disease. Effects of cessation are largest in this group — secondary-prevention cessation produces ~36% relative reduction in mortality post-MI, a larger effect than most cardiac pharmacotherapy.

Knowledge gaps

Long-term (decade+) outcomes of exclusive nicotine e-cigarette use without prior smoking history remain unestablished — the cohorts are too young. The dose-response curve at very low exposure (1–4 cig/day, intermittent social smoking) is still debated for cardiovascular endpoints; some data suggest near-linearity all the way to zero, others suggest a small floor. Effective cessation strategies for the highest-difficulty subpopulations (severe mental illness, chronic substance co-use) are less developed. The relative oncologic versus cardiovascular hazard of new combustible-tobacco alternatives (heat-not-burn) is still under investigation; current evidence suggests intermediate risk but with substantial uncertainty.

Category placement. Slotted under Breathing & Air because the route of exposure is respiratory and the most proximate organ damage is pulmonary. Medical & Healthcare was a runner-up but reads as too clinically-anchored for a behavioural entry; Lookmaxxing is a real-but-secondary consequence and would understate the longevity signal.

Scope coverage vs. brief. The brief named cardiovascular, lung function, multi-site cancer, skin, fertility, lifespan and post-cessation recovery. The article covers all of these end-to-end; cancer is summarised by site list rather than per-site breakdowns to avoid bloat, but each of the dimension scores reflects the holistic substance effect (per ./entry.md §1a).

Hard scoring calls.

focus = 1. The literature is mixed: acute nicotine has measurable cognitive effects, chronic smoking has hypoxia-mediated decrement, and quit-attempt withdrawal disrupts focus. Net cessation benefit is real but small. Held at 1 rather than 0 to keep the dimension honest about a real but minor signal.
cost_burden = 1 rather than 0. Quitting saves money in net terms, but the action itself (pharmacotherapy course) carries a few hundred dollars of cost when not covered. A reader without insurance coverage should see this as a real number.
beauty_cumulative = 4, not 5. The "smoker's face" data is strong but the trajectory is comparable to chronic sun exposure rather than transforming the underlying aging clock. Reserved 5 for interventions with a more singular aesthetic profile.
longevity = 5, evidence = 5. Both at ceiling and earned — this is the canonical maximal-evidence longevity hazard in modern medicine.

Separate-entry candidates.

Nicotine vaping / e-cigarettes — distinct substance, distinct (and evolving) risk profile, increasingly important harm-reduction route. Currently signposted from out-of-scope; warrants its own entry.
Secondhand smoke exposure — different population (non-smoker partners and children), different evidence base, deserves its own treatment.
Smokeless tobacco / snus — different substance, different cancer risk profile (oral > lung), Scandinavian harm-reduction debate is its own conversation.
Smoking cessation in pregnancy — overlapping but population-specific protocol (behavioural-first, NRT preferred over smoking, no e-cigs).

Future links. Once the above exist, this entry should cross-link to: nicotine vaping, alcohol (the highest-risk relapse co-substance), exercise (cardiovascular co-benefit), and any future entry on smoking cessation pharmacotherapy specifically.

Stakeholder caveat. The UK (NICE, former PHE) and US (CDC, FDA) public-health bodies disagree meaningfully on e-cigarette messaging — UK permissive, US cautious. Article takes the Cochrane evidence-based middle (effective cessation aid; long-term safety not fully established) rather than picking a side.